-
Gastrointestinal Endoscopy Clinics of... Jan 2024
Topics: Humans; Oncologists; Endoscopy
PubMed: 37973235
DOI: 10.1016/j.giec.2023.08.001 -
International Journal of Radiation... Feb 2022
Topics: Canada; Humans; Job Satisfaction; Radiation Oncologists; Radiation Oncology; Workforce
PubMed: 34998532
DOI: 10.1016/j.ijrobp.2021.09.049 -
International Journal of Radiation... Jun 2018
Topics: Deductibles and Coinsurance; Financing, Personal; Health Expenditures; Humans; Insurance, Major Medical; Oncologists
PubMed: 29726360
DOI: 10.1016/j.ijrobp.2017.11.046 -
Oral Oncology Sep 2016Transoral Robotic Surgery (TORS) is a fascinating new technology allowing for excellent functional outcomes after resection of head and neck tumors that previously... (Review)
Review
Transoral Robotic Surgery (TORS) is a fascinating new technology allowing for excellent functional outcomes after resection of head and neck tumors that previously required morbid surgical approaches for access. With a new technology, however, come new questions as to optimal patient selection and its impact on adjuvant therapy considerations. Here we review the issues most pertinent to a radiation oncologist adapting to the use of TORS. Patient selection, indications for adjuvant radiotherapy, radiation dose and target volumes are discussed. Finally, ongoing clinical trials and future directions are considered.
Topics: Chemotherapy, Adjuvant; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Mouth; Radiation Oncologists; Radiotherapy, Adjuvant; Robotic Surgical Procedures
PubMed: 27531879
DOI: 10.1016/j.oraloncology.2016.07.008 -
The Oncologist Apr 2023The merit-based incentive payment system (MIPS) is a value-based payment model created by the Centers for Medicare & Medicaid Services (CMS) to promote high-value care...
The merit-based incentive payment system (MIPS) is a value-based payment model created by the Centers for Medicare & Medicaid Services (CMS) to promote high-value care through performance-based adjustments of Medicare reimbursements. In this cross-sectional study, we examined the participation and performance of oncologists in the 2019 MIPS. Oncologist participation was low (86%) compared to all-specialty participation (97%). After adjusting for practice characteristics, higher MIPS scores were observed among oncologists with alternative payment models (APMs) as their filing source (mean score, 91 for APMs vs. 77.6 for individuals; difference, 13.41 [95% CI, 12.21, 14.6]), indicating the importance of greater organizational resources for participants. Lower scores were associated with greater patient complexity (mean score, 83.4 for highest quintile vs. 84.9 for lowest quintile, difference, -1.43 [95% CI, -2.48, -0.37]), suggesting the need for better risk-adjustment by CMS. Our findings may guide future efforts to improve oncologist engagement in MIPS.
Topics: Aged; Humans; United States; Medicare; Motivation; Cross-Sectional Studies; Oncologists; Reimbursement, Incentive
PubMed: 36847139
DOI: 10.1093/oncolo/oyad033 -
European Journal of Surgical Oncology :... Jan 2018The ability to provide optimal care to cancer patients depends on awareness of current evidence-based practices emanating from research or involvement in research where... (Review)
Review
BACKGROUND
The ability to provide optimal care to cancer patients depends on awareness of current evidence-based practices emanating from research or involvement in research where circumstances permit. The significant global variations in cancer-related research activity and its correlation to cancer-specific outcomes may have an influence on the care provided to cancer patients and their outcomes. The aim of this project is to develop a global curriculum in research literacy for the surgical oncologist.
MATERIALS AND METHODS
The leadership of the Society of Surgical Oncology and European Society of Surgical Oncology convened a global curriculum committee to develop a global curriculum in research literacy for the Surgical Oncologist.
RESULTS
A global curriculum in research literacy is developed to incorporate the required domains considered to be essential to interpret the published research or become involved in research activity where circumstances permit. The purpose of this curriculum is to promote research literacy for the surgical oncologist, wherever they are based. It does not mandate direct research participation which may not be feasible due to restrictions within the local health-care delivery environment, socio-economic priorities and the educational environment of the individual institution where they work.
CONCLUSIONS
A global curriculum in research literacy is proposed which may promote research literacy or encourage involvement in research activity where circumstances permit. It is hoped that this will enhance cancer-related research activity, promote awareness of optimal evidence-based practices and improve outcomes for cancer patients globally.
Topics: Biomedical Research; Curriculum; Humans; Literacy; Medical Oncology; Neoplasms; Oncologists; Surgical Oncology
PubMed: 29242017
DOI: 10.1016/j.ejso.2017.07.017 -
JCO Global Oncology Mar 2022
Topics: Health Personnel; Humans; Medical Oncology; Oncologists; Sri Lanka; Workload
PubMed: 35230874
DOI: 10.1200/GO.21.00429 -
Mayo Clinic Proceedings Nov 2021
Topics: Canada; History; Humans; Medical Oncology; Physicians, Women; Radiation Oncologists; Radiotherapy
PubMed: 34736618
DOI: 10.1016/j.mayocp.2021.05.018 -
Journal of Cancer Research and... 2016Superior vena cava syndrome is referred to as a constellation of symptoms and signs caused by obstruction of superior vena cava. It can occur due to both benign and... (Review)
Review
Superior vena cava syndrome is referred to as a constellation of symptoms and signs caused by obstruction of superior vena cava. It can occur due to both benign and malignant causes with the latter being the predominant. There is a paradigm shift in the approach to manage this condition. It is no longer considered a medical emergency and histological diagnosis is necessary before treatment. This article reviews the causes, symptoms, pathophysiology, and overall management policy which have changed over decades.
Topics: Humans; Neoplasm Grading; Neoplasms; Radiation Oncologists; Radiation Oncology; Superior Vena Cava Syndrome
PubMed: 27461602
DOI: 10.4103/0973-1482.177503 -
European Journal of Surgical Oncology :... Aug 2018Chest wall inflammatory and lymphangitic breast cancer represents a clinical spectrum and a model disease. Inflammation and the immune response have a role in the... (Review)
Review
Chest wall inflammatory and lymphangitic breast cancer represents a clinical spectrum and a model disease. Inflammation and the immune response have a role in the natural history of this special clinical presentation. Preclinical models and biomarker studies suggest that inflammatory breast cancer comprises a more important role for the tumour microenvironment, including immune cell infiltration and vasculogenesis, especially lympho-angiogenesis. Across this clinical continuum of the chest wall disease there is an important role of the inflammation cascade. The activation of mature dendritic cells (DCs) through toll like receptors (TLRs) or by inflammatory cytokines converts immature DCs into mature DCs that present specific antigen to T cells, thereby activating them. Maturation of DCs is accompanied by co-stimulatory molecules and secretion of inflammatory cytokines polarizing lymphocytic, macrophages and fibroblast infiltration. It is unknown whether immune cells associated to the IBC microenvironment play a role in this scenario to transiently promote epithelial to mesenchymal transition (EMT) in these cells. Immune and microenvirnment factors can induce phenotypic, morphological, and functional changes in breast cancer cells. We can hypothesize that similar inflammatory conditions in vivo may support both the rapid metastasis and tight tumor emboli that are characteristic of chest wall disease and that targeted anti-inflammatory therapy may play a role in this patient population. The current review will review biological and clinical data of this special condition.
Topics: Cell Differentiation; Clinical Competence; Female; Humans; Inflammatory Breast Neoplasms; Oncologists; Thoracic Diseases; Thoracic Wall; Tumor Microenvironment
PubMed: 30032791
DOI: 10.1016/j.ejso.2018.05.019